Current clinical guidelines from organizations like the American Gastroenterological Association (2022), the Endocrine Society, and the American Association of Clinical Endocrinology support long-term pharmacotherapy for obesity management
The Medicare GLP-1 Bridge will provide coverage of three GLP-1s (Wegovy, Zepbound, and Foundayo) that have been approved by the FDA for chronic weight management in adults with obesity (BMI of 30 or more) or adults with overweight (BMI of 27 or more) plus a weight-related comorbid condition
Tsutamoto S, Iwasaki Y, Shinohara A, Imamiya R, Samukawa K, Kawada-Matsuo M, et al
This not only supports body fat loss but also elevates overall energy levels, enabling better physical performance and endurance (6)
The American journal of clinical nutrition, 2000
J Med Genet 15(6): 40913